AS057278, a potent in vitro (IC50=0.91 mM) and ex vivo (ED50=2.2-3.95 mM) DAAO inhibitor, was able to increase d-serine fraction in rat cortex and midbrain (10 mg/kg i.v.). AS057278 was able to normalize phencyclidine (PCP)-induced prepulse inhibition after acute (80 mg/kg) and chronic (20 mg/kg b.i.d.) oral administration in mice. AS057278 after oral chronic treatment (10 mg/kg b.i.d.) was able to normalize PCP-induced hyperlocomotion[2]. Pretreatment with AS057278 significantly suppressed the DA release induced by d-Trp[3]. The effect of insulin in restoration of PDHP phosphatase activity of starved rats was not mimicked by AS057278[4]. Rats made tolerant to nicotinic acid also became tolerant to both AS057278 and to pyridyl-3-tetrazole and rats made tolerant to these antilipolytic agents were also tolerant to nicotinic acid[5].
搜索
